Schrödinger, Inc. SDGR R2K
Healthcare · Health Information Services · United States
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
READ MORE ›$15.20
-29.69% 1Y
Market & Price
Market Cap
$1.14B
Current Price
$15.20
High / Low (52W)
$26.69 / $11.07
Beta
1.58
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$4.21
Price to Book
3.61
P/S
4.46
EV/EBITDA
-5.31
Dividend Yield
-
Profitability & Returns
ROCE
-31.08%
ROE
-30.12%
ROA
-14.96%
Profit Margin
-40.60%
Op Margin
-83.29%
EPS (Latest Qtr)
$-0.81
EPS (TTM)
$-1.40
Balance Sheet & Liquidity
Debt/Equity
0.34
Quick Ratio
2.64
Current Ratio
2.74
Debt
$107.01M
Total Assets
$726.16M
Current Assets
$519.26M
Working Capital
$330.13M
Ownership
Promoter Holding
2.91%
Chg in Prom Hold
-
FII / Inst Holding
97.95%
Chg in FII Hold
-0.01%
Financial Snapshot
Enterprise Value
$843.80M
Total Revenue (TTM)
$254.90M
EBITDA
$-158.89M
Free Cash Flow
$-49.42M
Operating Cash Flow
$-145.00M
Shares Outstanding
65.56M
Gross Margin
55.33%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
12.24%
Profit 5Y
10.26%
Revenue (YoY)
-1.60%
Earnings (YoY)
-
PROS
- Compounding revenue at 12.2% over 5 years.
- Profit CAGR of 10.3% over 5 years.
CONS
- Trading 43.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SDGR Schrödinger, Inc. R2K | 15.20 | - | $1.14B | - | -31.08% | -30.12% | 12.24% | 10.26% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.74M | 19.01M | 19.96M | 26.17M | 23.09M | 25.80M | 32.13M | 29.78M | 29.85M | 48.66M | 38.47M | 36.98M | 64.78M | 35.19M | 42.57M | 36.60M | 47.33M | - | - | 59.55M | 54.76M | 54.32M | 87.23M | 58.59M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.43M | 28.60M | 26.29M | 29.94M | 29.04M |
| Gross Profit | 13.00M | 9.85M | 10.71M | 15.62M | 13.58M | 15.27M | 16.16M | 11.98M | 11.12M | 27.98M | 17.13M | 17.20M | 45.69M | 13.81M | 23.64M | 18.89M | 31.34M | - | - | 31.12M | 26.16M | 28.04M | 57.29M | 29.55M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 82.01M | 79.06M | 73.99M | 74.45M | 78.34M |
| Operating Income | -5.61M | -13.96M | -11.29M | -11.80M | -17.09M | -15.45M | -23.91M | -30.34M | -34.67M | -28.64M | -43.47M | -46.16M | -30.50M | -61.13M | -56.19M | -67.43M | -52.73M | - | - | -50.89M | -52.90M | -45.95M | -17.16M | -48.79M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -49.30M | -51.37M | -44.48M | -15.72M | -47.32M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59.78M | -42.89M | -32.63M | 32.97M | -59.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.00K | 287.00K | 162.00K | 462.00K | 408.00K |
| Net Income | -5.79M | -500.00K | -11.51M | -13.83M | -3.35M | 3.85M | -29.00K | -34.64M | -35.01M | -34.44M | -47.69M | -39.85M | 129.14M | 4.28M | -62.02M | -54.72M | -54.05M | - | - | -59.81M | -43.17M | -32.80M | 32.51M | -60.03M |
| Diluted EPS | - | - | -0.26 | - | - | 0.05 | - | -0.49 | -0.49 | -0.48 | -0.67 | -0.56 | 1.75 | 0.06 | -0.86 | -0.76 | -0.74 | -0.52 | - | -0.82 | -0.59 | -0.45 | - | -0.81 |
| R&D Expense | 8.44M | 9.53M | 10.35M | 13.70M | 16.66M | 17.02M | 21.45M | 21.09M | 23.22M | 27.82M | 31.12M | 32.88M | 40.74M | 42.70M | 46.83M | 50.61M | 50.84M | 50.98M | - | 45.84M | 43.14M | 42.76M | - | 43.82M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.54M | 108.09M | - | 180.96M | 216.67M | 207.54M | 255.87M |
| Cost of Revenue | - | - | - | 79.93M | 75.97M | 75.46M | 113.25M |
| Gross Profit | 49.09M | 63.47M | - | 101.02M | 140.69M | 132.08M | 142.61M |
| Operating Expenses | - | - | - | 247.84M | 318.14M | 341.38M | 309.51M |
| Operating Income | -38.72M | -60.92M | - | -146.82M | -177.45M | -209.30M | -166.90M |
| EBITDA | - | - | - | -142.47M | -171.90M | -203.14M | -160.87M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -149.12M | 42.92M | -185.71M | -102.33M |
| Tax Provision | - | - | - | 63.00K | 2.20M | 1.41M | 939.00K |
| Net Income | -24.57M | -24.46M | - | -149.19M | 40.72M | -187.12M | -103.27M |
| Diluted EPS | - | -0.41 | - | -2.10 | 0.54 | -2.57 | -1.41 |
| R&D Expense | 39.40M | 64.69M | 90.90M | 126.37M | 181.77M | 201.78M | 173.14M |
Compounded Sales Growth
| 5 Years: | 12.24% |
| 1 Year: | -1.60% |
Compounded Profit Growth
| 5 Years: | 10.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -29.69% |
| 6 Months: | -12.89% |
| 3 Months: | +26.04% |
| 1 Month: | +29.25% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 155.27M | 746.26M | - | 688.59M | 802.96M | 823.23M | 726.16M |
| Current Assets | - | - | - | - | 533.99M | 567.80M | 634.99M | 519.26M |
| Cash & Equivalents | - | 25.99M | 202.30M | - | 90.47M | 155.31M | 147.33M | 230.52M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 55.95M | 65.99M | 235.69M | 83.04M |
| Total Liabilities | - | 57.01M | 122.24M | - | 240.68M | 254.40M | 401.78M | 362.11M |
| Current Liabilities | - | 45.02M | 73.20M | - | 108.80M | 133.67M | 191.75M | 189.14M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 116.49M | 127.88M | 117.83M | 109.23M |
| Total Equity | -71.56M | -93.36M | 624.01M | - | 447.89M | 548.56M | 421.44M | 364.05M |
| Shares Outstanding | - | - | - | - | 71.33M | 72.14M | 72.87M | 73.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -26.06M | 16.76M | - | -119.68M | -136.73M | -157.37M | 13.90M |
| Investing Cash Flow | -53.85M | -381.72M | - | 90.02M | 193.03M | 148.84M | 57.90M |
| Financing Cash Flow | 28.68M | 541.27M | - | 2.11M | 9.05M | 10.12M | 2.93M |
| Capital Expenditure | -1.84M | -2.54M | - | -8.01M | -13.40M | -7.31M | -1.44M |
| Free Cash Flow | -27.89M | 14.22M | - | -127.70M | -150.14M | -164.68M | 12.46M |
| Net Change in Cash | - | - | - | -27.55M | 65.35M | 1.59M | 74.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 57.4% | 58.7% | - | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating Margin % | -45.3% | -56.4% | - | -81.1% | -81.9% | -100.8% | -65.2% |
| Net Margin % | -28.7% | -22.6% | - | -82.4% | 18.8% | -90.2% | -40.4% |
| ROE % | 26.3% | -3.9% | - | -33.3% | 7.4% | -44.4% | -28.4% |
| ROCE % | -35.1% | -9.1% | - | -25.3% | -26.5% | -33.1% | -31.1% |
Shareholding Pattern
Insiders
2.91%
Institutions
97.95%
Public Float
100.88%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.76% | 9.68M | $147.11M |
| 2 | Gates Foundation Trust | 10.65% | 6.98M | $106.12M |
| 3 | Rubric Capital Management LP | 9.15% | 6.00M | $91.20M |
| 4 | Vanguard Portfolio Management LLC | 5.89% | 3.86M | $58.71M |
| 5 | Sumitomo Mitsui Trust Group, Inc. | 4.87% | 3.19M | $48.50M |
| 6 | Amova Asset Management Americas Inc | 4.87% | 3.19M | $48.50M |
| 7 | Massachusetts Financial Services Co. | 4.10% | 2.68M | $40.81M |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4.06% | 2.66M | $40.44M |
| 9 | Vanguard Capital Management LLC | 3.97% | 2.60M | $39.59M |
| 10 | State Street Corporation | 3.34% | 2.19M | $33.31M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SDGR
No recent headlines available.